Abstract
Simple SummaryPapillary thyroid carcinoma (PTC) in pediatric patients shows different characteristics compared with PTC in adults. In this large mono-institutional cohort of pediatric PTCs, tumor tissue samples have been analyzed for point mutations and fusions. Overall, molecular alterations were detected in 131 out of 163 PTCs (80%). Fusion-driven PTCs showed more aggressive clinico-pathological features compared to mutation-driven and wild-type cases. These results highlight the importance of testing pediatric PTCs for gene rearrangement in routine characterization of tumors.Papillary thyroid carcinoma (PTC) presents distinct clinico-pathological and molecular differences in children compared with adult patients. Whether the presence of rearrangements or point mutations is associated with aggressive PTC clinical presentation is still controversial. In this study, PTCs diagnosed in patients aged less than 18 years were retrospectively searched from the institutional archive and tumor tissue was tested for point mutations in BRAF and RAS genes and for rearrangements in RET, NTRK1, NTRK3, ALK, PPARG, BRAF and THADA. A total of 163 PTCs were analyzed. Point mutations were found in 83 (51%) and gene fusions in 48 cases (30%). The most frequent alteration was the BRAFV600E mutation (36.8%), followed by NTRK3 fusion (11%), NRAS mutation (10.4%) and RET fusion (10.4%). Fusion-driven PTCs showed more frequently infiltrative growth, larger tumors, extrathyroidal extension and N1b disease. PTCs showing solid growth pattern were significantly enriched in gene fusions. This is one of the largest cohorts of pediatric PTCs. Fusion-driven tumors most frequently show aggressive pathological features; the search for rearrangements, especially in tumors with solid areas, could improve the characterization of pediatric PTCs and offer possible therapeutic options.
Highlights
Papillary thyroid carcinoma (PTC) is the most common malignancy of the endocrine system
According to the American Thyroid Association (ATA) guidelines for pediatric nodules and differentiated thyroid cancer (DTC), patients aged ≤18 years should be included in the pediatric age group
Our results show that gene fusions, mainly present in younger patients and in solid growth pattern PTCs, correlate with aggressive pathological tumor features
Summary
Papillary thyroid carcinoma (PTC) is the most common malignancy of the endocrine system. When occurring in pediatric age, PTC presents different clinico-pathological characteristics compared with PTC in adult patients [1]. The histology of PTC in children could differ from that generally observed in adults: rare variants, such as the diffuse sclerosing variant, can represent a common finding in pediatric PTC cohorts [5]. According to the American Thyroid Association (ATA) guidelines for pediatric nodules and differentiated thyroid cancer (DTC), patients aged ≤18 years should be included in the pediatric age group. It is not clear whether further age subgroups (i.e., less than 10–15-year-old children) with different clinico-pathological characteristics could be identified [1]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.